Theriva Biologics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Theriva Biologics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $0 | Mar 30, 2012 |
| FY2011 | Dec 31, 2010 | $2.61M | Mar 30, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($18.35M) | Mar 25, 2024 |
| FY2023 | Dec 31, 2022 | ($19.69M) | Mar 25, 2024 |
| FY2022 | Sep 30, 2022 | ($4.49M) | Mar 30, 2023 |
| FY2022 | Jun 30, 2022 | ($4.48M) | Mar 30, 2023 |
| FY2022 | Mar 31, 2022 | ($4.27M) | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | ($14.27M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($10.04M) | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | ($15.30M) | Mar 4, 2021 |
| FY2018 | Dec 31, 2018 | ($3.19M) | Feb 27, 2019 |
| FY2018 | Sep 30, 2018 | ($3.69M) | Feb 27, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($24.05M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($26.35M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($21.43M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($21.58M) | Mar 25, 2024 |
| FY2022 | Sep 30, 2022 | ($4.99M) | Mar 30, 2023 |
| FY2022 | Jun 30, 2022 | ($5.03M) | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | ($14.27M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($10.16M) | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | ($15.66M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($17.57M) | Feb 20, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.60M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $12.03M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $14.31M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $11.72M | Mar 25, 2024 |
| FY2022 | Sep 30, 2022 | $2.57M | Mar 30, 2023 |
| FY2022 | Jun 30, 2022 | $3.49M | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $7.80M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $5.13M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $11.08M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $11.84M | Feb 20, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.67M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($16.94M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($19.00M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($19.08M) | Mar 25, 2024 |
| FY2022 | Sep 30, 2022 | ($13.71M) | Mar 30, 2023 |
| FY2022 | Jun 30, 2022 | ($9.26M) | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | ($12.89M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($12.17M) | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | ($13.87M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($17.28M) | Feb 20, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $202.0K | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $116.0K | Mar 25, 2024 |
| FY2022 | Sep 30, 2022 | $25.0K | Mar 30, 2023 |
| FY2022 | Jun 30, 2022 | $14.0K | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $14.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $9.0K | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $7.0K | Feb 20, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.24M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $35.35M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $55.22M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $71.86M | Mar 25, 2024 |
| FY2022 | Sep 30, 2022 | $77.11M | Mar 30, 2023 |
| FY2022 | Jun 30, 2022 | $80.64M | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $70.37M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $8.41M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $17.24M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $30.14M | Feb 20, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.86M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $16.29M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $15.52M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $17.30M | Mar 25, 2024 |
| FY2022 | Sep 30, 2022 | $17.99M | Mar 30, 2023 |
| FY2022 | Jun 30, 2022 | $18.42M | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $4.96M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $3.15M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $5.75M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $3.69M | Feb 20, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2022 | $56.39M | Mar 30, 2023 |
| FY2022 | Jun 30, 2022 | $62.22M | Mar 30, 2023 |
| FY2021 | Dec 31, 2021 | $65.41M | Mar 16, 2022 |
| FY2021 | Dec 31, 2020 | ($4.77M) | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $1.82M | Mar 4, 2021 |
| FY2019 | Sep 30, 2019 | $4.93M | Feb 20, 2020 |
| FY2019 | Dec 31, 2018 | $17.07M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | ($1.50M) | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $3.85M | Feb 22, 2018 |
| FY2016 | Dec 31, 2015 | $16.05M | Mar 2, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Mar 6, 2025 |
| FY2025 | Dec 31, 2023 | $5.70M | Mar 12, 2026 |
| FY2023 | Dec 31, 2022 | $5.53M | Mar 25, 2024 |
| FY2022 | Sep 30, 2022 | $5.22M | Mar 30, 2023 |
| FY2022 | Jun 30, 2022 | $6.22M | Mar 30, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($358.71M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($334.97M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($309.32M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($290.97M) | Mar 25, 2024 |
| FY2022 | Sep 30, 2022 | ($284.52M) | Mar 30, 2023 |
| FY2022 | Jun 30, 2022 | ($280.03M) | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | ($271.28M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($248.09M) | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | ($235.54M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($219.46M) | Feb 20, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.06M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $11.61M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $23.18M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $41.79M | Mar 25, 2024 |
| FY2022 | Sep 30, 2022 | $50.49M | Mar 30, 2023 |
| FY2022 | Jun 30, 2022 | $52.27M | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $67.33M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $6.23M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $15.05M | Mar 4, 2021 |
| FY2018 | Feb 28, 2019 | $26.00M | Feb 27, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.67M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $92.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $162.0K | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $221.0K | Mar 25, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (19) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (28) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 25, 2024 |
| FY2022 | Sep 30, 2022 | 0 | Mar 30, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | (1) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 16, 2022 |
| FY2018 | Dec 31, 2018 | (1) | Feb 27, 2019 |
| FY2018 | Sep 30, 2018 | 0 | Feb 27, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (19) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (28) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 25, 2024 |
| FY2022 | Sep 30, 2022 | 0 | Mar 30, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | (1) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 16, 2022 |
| FY2018 | Dec 31, 2018 | (1) | Feb 27, 2019 |
| FY2018 | Sep 30, 2018 | 0 | Feb 27, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 35.69M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 2.78M | Mar 12, 2026 |
| FY2025 | Aug 26, 2024 | 1.01M | Mar 12, 2026 |
| FY2025 | Aug 25, 2024 | 25.13M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 686,219 | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 15.12M | Mar 25, 2024 |
| FY2022 | Sep 30, 2022 | 15.84M | Mar 30, 2023 |
| FY2023 | Jul 25, 2022 | 15.84M | Mar 25, 2024 |
| FY2023 | Jul 24, 2022 | 158.44M | Mar 25, 2024 |
| FY2022 | Jun 30, 2022 | 15.84M | Mar 30, 2023 |